BIIB logoBIIB
Biogen Inc

18,678
Loading...
Loading...
News
all
press releases
LLY Gets EU Approval for Alzheimer's Drug & FDA Nod to Cancer Therapy
Eli Lilly secures EU approval for Alzheimer's drug Kisunla and gains FDA nod to breast cancer therapy Inluriyo.
Zacks·23h ago
News Placeholder
More News
News Placeholder
Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America
Generic drugs remain exempt, while duties will apply to prescription, biologic, specialty and over-the-counter medicines.
Stocktwits·1d ago
News Placeholder
BIIB's sNDA for Higher Dose of SMA Drug Spinraza Gets FDA's CRL
FDA issues CRL to Biogen's regulatory filing seeking approval for a higher dose of SMA drug, Spinraza. The company plans prompt resubmission.
Zacks·3d ago
News Placeholder
IONS' Rare Neurological Disease Drug Meets Late-Stage Study Goal
Ionis' zilganersen hits its phase III goal in Alexander disease, paving the way for a potential FDA filing in early 2026.
Zacks·4d ago
News Placeholder
Biogen Gets EU Nod for First Postpartum Depression Drug
BIIB secures EU approval for Zurzuvae, the first oral treatment for postpartum depression, boosting its long-term growth prospects.
Zacks·9d ago
News Placeholder
Will AbbVie's Neuroscience Portfolio Continue to Aid Top-line Growth?
ABBV's expanding neuroscience portfolio, led by Botox, Vraylar and new launches like Vyalev, continues to fuel top-line growth.
Zacks·23d ago
News Placeholder
IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride
Ionis surges to a 52-week high after Tryngolza shows strong triglyceride reductions and cuts acute pancreatitis risk by 85% in late-stage studies.
Zacks·24d ago
News Placeholder
Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales
Eli Lilly's growing lineup beyond Mounjaro and Zepbound, including Omvoh and Jaypirca, is set to fuel revenue growth through 2025.
Zacks·25d ago
News Placeholder
UK Regulator Approves Biogen’s Drug For Treating Postnatal Depression
Zuranolone is the first oral treatment for postnatal depression approved in the UK, the agency said.
Stocktwits·1mo ago
News Placeholder
DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26
Denali Therapeutics posts narrower-than-expected Q2 loss. The company advances multiple rare disease therapies toward potential approvals.
Zacks·2mo ago

Latest BIIB News

View

Advertisement|Remove ads.

Advertisement|Remove ads.